Madrigal Pharmaceuticals/MDGL
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Ticker
MDGL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
West Conshohocken, United States
Employees
376
Website
www.madrigalpharma.com
MDGL Metrics
BasicAdvanced
$5.8B
Market cap
-
P/E ratio
-$23.21
EPS
-0.34
Beta
-
Dividend rate
Price and volume
Market cap
$5.8B
Beta
-0.34
Financial strength
Current ratio
9.393
Quick ratio
9.262
Long term debt to equity
13.774
Total debt to equity
13.774
Interest coverage (TTM)
-31.95%
Management effectiveness
Return on assets (TTM)
-40.13%
Return on equity (TTM)
-88.78%
Valuation
Price to book
6.7
Price to tangible book (TTM)
6.7
Price to free cash flow (TTM)
-13.3
Growth
Earnings per share change (TTM)
28.35%
3-year earnings per share growth
18.18%
What the Analysts think about MDGL
Analyst Ratings
Majority rating from 15 analysts.
MDGL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$148M
31.58%
Profit margin
0.00%
NaN%
MDGL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$4.69
-$5.34
-$5.68
-$7.38
-
Expected
-$4.58
-$4.93
-$5.28
-$6.29
-$7.56
Surprise
2.37%
8.42%
7.49%
17.42%
-
MDGL News
AllArticlesVideos
Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts
CNBC Television·3 weeks ago
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
Seeking Alpha·3 weeks ago
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Madrigal Pharmaceuticals stock?
Madrigal Pharmaceuticals (MDGL) has a market cap of $5.8B as of July 04, 2024.
What is the P/E ratio for Madrigal Pharmaceuticals stock?
The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of July 04, 2024.
Does Madrigal Pharmaceuticals stock pay dividends?
No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Madrigal Pharmaceuticals dividend payment date?
Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.34. This means that it has an inverse relation to market volatility.
Buy or sell Madrigal Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.